CA2834255C - Peptide for inducing regeneration of tissue and use thereof - Google Patents

Peptide for inducing regeneration of tissue and use thereof Download PDF

Info

Publication number
CA2834255C
CA2834255C CA2834255A CA2834255A CA2834255C CA 2834255 C CA2834255 C CA 2834255C CA 2834255 A CA2834255 A CA 2834255A CA 2834255 A CA2834255 A CA 2834255A CA 2834255 C CA2834255 C CA 2834255C
Authority
CA
Canada
Prior art keywords
amino acid
acid sequence
peptide
seq
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2834255A
Other languages
English (en)
French (fr)
Other versions
CA2834255A1 (en
Inventor
Katsuto Tamai
Takehiko Yamazaki
Tsutomu KANEZAKI
Shigeru Sakurai
Yukiko Noguchi
Mayumi Endo
Natsumi HAMABUCHI
Kana NAITO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
StemRIM Inc
University of Osaka NUC
Original Assignee
Osaka University NUC
StemRIM Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, StemRIM Inc filed Critical Osaka University NUC
Publication of CA2834255A1 publication Critical patent/CA2834255A1/en
Application granted granted Critical
Publication of CA2834255C publication Critical patent/CA2834255C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
CA2834255A 2011-04-26 2012-04-03 Peptide for inducing regeneration of tissue and use thereof Active CA2834255C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2011098270 2011-04-26
JP2011-098270 2011-04-26
JP2011-219454 2011-10-03
JP2011219454 2011-10-03
PCT/JP2012/059113 WO2012147470A1 (ja) 2011-04-26 2012-04-03 組織再生を誘導するためのペプチドとその利用

Publications (2)

Publication Number Publication Date
CA2834255A1 CA2834255A1 (en) 2012-11-01
CA2834255C true CA2834255C (en) 2021-11-02

Family

ID=47071995

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2834255A Active CA2834255C (en) 2011-04-26 2012-04-03 Peptide for inducing regeneration of tissue and use thereof

Country Status (12)

Country Link
US (4) US10364276B2 (OSRAM)
EP (2) EP3358011B1 (OSRAM)
JP (6) JP6069191B2 (OSRAM)
KR (2) KR101992807B1 (OSRAM)
CN (3) CN107188948B (OSRAM)
AU (4) AU2012248676B2 (OSRAM)
CA (1) CA2834255C (OSRAM)
DK (2) DK2703487T3 (OSRAM)
ES (2) ES2788394T3 (OSRAM)
PL (2) PL3358011T3 (OSRAM)
PT (2) PT3358011T (OSRAM)
WO (1) WO2012147470A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0911513A2 (pt) 2008-04-30 2016-07-12 Genomix Co Ltd métodos e agentes para coleta de células tronco da medula óssea funcionais in vivo com alta eficiência
CN104825491A (zh) 2009-10-28 2015-08-12 吉诺米克斯股份有限公司 利用骨髓间充质干细胞和/或多能干细胞的血中动员的组织再生促进剂
CA2889275C (en) * 2012-10-25 2021-06-15 Katsuto Tamai Novel method for treating cardiac infarction using hmgb1 fragment
RU2649069C2 (ru) 2012-10-25 2018-04-02 Дженомикс Ко., Лтд. Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1
US10961531B2 (en) 2013-06-05 2021-03-30 Agex Therapeutics, Inc. Compositions and methods for induced tissue regeneration in mammalian species
WO2016179584A1 (en) 2015-05-07 2016-11-10 University Of South Florida Modified ube3a gene for a gene therapy approach for angelman syndrome
AU2016366158B2 (en) 2015-12-07 2023-02-23 Agex Therapeutics, Inc. Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells
CN106995796A (zh) * 2016-01-26 2017-08-01 李建业 基于细胞因子的细胞处理方法、试剂盒及冻干粉
EP3448415A4 (en) * 2016-04-29 2019-11-06 Araim Pharmaceuticals, Inc. TREATMENT-PROOFING PEPTIDES FOR THE PREVENTION AND TREATMENT OF DISEASES AND DISORDERS RELATED TO TISSUE DAMAGE
EP3515419A4 (en) * 2016-09-21 2020-06-10 Stephen H. Thorne High mobility group box i mutant
MX2019008949A (es) 2017-01-27 2019-10-07 Stemrim Inc Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica.
WO2018186480A1 (ja) * 2017-04-07 2018-10-11 株式会社ステムリム 線維性疾患の治療薬
CA3059544A1 (en) * 2017-04-25 2018-11-01 Shionogi & Co., Ltd. Peptide for inducing regeneration of tissue, and use thereof
US12421498B2 (en) 2017-12-01 2025-09-23 StemRIM Inc. Ectodermal mesenchymal stem cells and method for producing same
CN111542335A (zh) * 2017-12-01 2020-08-14 斯特姆里姆有限公司 炎症性肠病的治疗药
WO2019156137A1 (ja) 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
BR112021005982A2 (pt) * 2018-10-05 2021-06-29 StemRIM Inc. peptídeo possuindo atividade de mobilização de células-tronco mesenquimais
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
WO2020085506A1 (ja) * 2018-10-25 2020-04-30 国立大学法人大阪大学 軟骨疾患の治療薬
JP7429454B2 (ja) * 2019-03-26 2024-02-08 国立大学法人 新潟大学 ペプチド及びその使用
CN109957015A (zh) * 2019-04-01 2019-07-02 中国人民解放军海军军医大学国家肝癌科学中心 一种hmgb1封闭性抗体的制备方法及其应用
JP2023512392A (ja) * 2019-11-12 2023-03-27 オックスフォード ユニバーシティ イノベーション リミテッド 組織再生の促進に有用なｈｍｇｂ１に関連するポリペプチド、それを含む組成物、及びその使用
JP7672636B2 (ja) * 2020-04-03 2025-05-08 株式会社ステムリム 間葉系幹細胞の動員活性を有するペプチド
WO2021215375A1 (ja) 2020-04-20 2021-10-28 塩野義製薬株式会社 Ｈｍｇｂ１部分ペプチドを含有する製剤
US20250019405A1 (en) * 2020-04-22 2025-01-16 Chulalongkorn University A Composition and A Method of Rejuvenating DNA and Preventing DNA Damage
EP4257703A4 (en) * 2020-12-07 2025-06-04 Samsung Life Public Welfare Foundation Method for selecting mesenchymal stem cells with improved self-sustainability and thereby selected mesenchymal stem cells
JP2024518125A (ja) * 2021-05-19 2024-04-24 オックスフォード ユニバーシティ イノベーション リミテッド 組織再生の促進に有用なｈｍｇｂ１関連ポリペプチド、それを含む組成物及びその使用
CA3233234A1 (en) 2021-09-30 2023-04-06 Katsuto Tamai Drug for treating fatty liver and nonalcoholic steatohepatitis
CN116983471B (zh) * 2023-06-07 2024-03-08 华中科技大学同济医学院附属协和医院 一种基于α-螺旋双亲性多肽的超分子共组装凝胶的制备方法及应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5238680B2 (OSRAM) 1972-12-27 1977-09-30
US4732155A (en) 1985-08-27 1988-03-22 The Children's Medical Center Corporation Implantable chemoattractant system
US5658894A (en) 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5661127A (en) 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
JP3018313B2 (ja) 1996-02-23 2000-03-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
ATE440602T1 (de) 1999-07-28 2009-09-15 Univ Leland Stanford Junior Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion
EP1263931A4 (en) 1999-11-05 2009-07-15 Gerigene Medical Corp INCREASE AND REPAIR OF IMPERFECTIONS OF SOFT TISSUES RELATED TO AGE
EP1114862A3 (de) 1999-11-17 2003-08-06 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
AU2001243288B2 (en) 2000-02-24 2005-11-24 Life Technologies Corporation Simultaneous stimulation and concentration of cells
JP3421741B2 (ja) 2000-05-18 2003-06-30 筑波大学長 人工骨髄、血球細胞の増殖方法
US20040191246A1 (en) 2003-02-26 2004-09-30 Connelly Patrick R. Process for in vivo treatment of specific biological targets in bodily fluid
US7754217B2 (en) 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
EP1390058A2 (en) 2001-04-30 2004-02-25 Switch Biotech Aktiengesellschaft Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
DE10121254A1 (de) 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
CN100447154C (zh) 2001-05-15 2008-12-31 费因斯坦医学研究学院 利用hmg片段作为抗炎症试剂
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
JPWO2003043651A1 (ja) 2001-11-19 2005-03-10 協和醗酵工業株式会社 多分化能幹細胞を組織から末梢血へ動員する薬剤
DK1921133T3 (en) 2001-12-07 2015-08-24 Cytori Therapeutics Inc System for processing lipoaspiratceller
FR2833609B1 (fr) 2001-12-19 2004-12-03 Natural Implant Dispositif de prelevement cellulaire ou tissulaire en phase active et utilisations
EP1519957B1 (en) 2002-07-03 2009-03-04 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
WO2004004770A1 (en) 2002-07-05 2004-01-15 Universite Laval Chemotactic factor inhibitor for modulating inflammatory reactions
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
WO2004046345A2 (en) 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Use of hmgb fragments as anti-inflammatory agents
US20040156851A1 (en) 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
AU2004203732A1 (en) 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Uses of HMGB, HMGN, HMGA proteins
DE602004017148D1 (de) 2003-03-28 2008-11-27 Univ Laval S100 protein als aktivator neutrophiler zellen zur verminderung der neutropenie bei der krebsbehandlung
CN1193092C (zh) 2003-03-28 2005-03-16 浙江大学 骨髓间充质干细胞分离和体外扩增培养方法
US20090069227A9 (en) 2003-04-29 2009-03-12 Capogrossi Maurizio C Use of HMGB1 to promote stem cell migration and/or proliferation
US20050014255A1 (en) 2003-05-29 2005-01-20 Board Of Regents, The University Of Texas System Stem cells for clinical and commercial uses
WO2005025604A2 (en) 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
CN1878793A (zh) * 2003-09-11 2006-12-13 鉴定医疗有限公司 拮抗hmgb1的单克隆抗体
ITRM20040058A1 (it) 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
WO2006008779A1 (en) 2004-07-20 2006-01-26 Provincia Italiana Della Congregazione Dei Figli Dell'immacolata Concezione-Istituto Dermopatico Dell'immacolata Use of hmgb1 for wound healing
MX2007001155A (es) 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
CA2579094C (en) * 2004-09-03 2014-12-02 Creabilis Therapeutics S.P.A. Use of polypeptides obtained through systematic mutations of single amino acids of human and non-human box-a of hmgb1 to prevent and/or antagonize pathologies induced by hmgb1
AU2005333602B2 (en) 2004-10-22 2012-04-12 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
KR100593397B1 (ko) 2004-10-27 2006-06-28 한국원자력연구소 중배엽 줄기세포 및/또는 ｐ 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제
WO2006047820A1 (en) 2004-11-01 2006-05-11 Newsouth Innovations Pty Limited Use of calgranulin a and b in the promotion and inhibition of mineralized tissue formation
ITRM20050032A1 (it) 2005-01-21 2006-07-22 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica.
WO2006080434A1 (ja) 2005-01-27 2006-08-03 Japan Health Sciences Foundation 間葉系幹細胞を含む細胞シート
CN101146559B (zh) 2005-03-23 2012-09-05 生物安全股份有限公司 用于再生医学的收集、处理和移植包括成人干细胞的细胞亚群的集成系统
KR100775958B1 (ko) * 2005-03-30 2007-11-13 김정문 조직재생 기능을 가지는 비활성 폴리펩티드 및 그 제조방법
WO2006114805A2 (en) 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
US20100280493A1 (en) 2005-06-23 2010-11-04 Asha Nayak Methods and Systems for Treating Injured Cardiac Tissue
WO2007015546A1 (ja) 2005-08-04 2007-02-08 Genomix Co., Ltd 間葉系幹細胞誘導剤及び組織再生促進剤並びに間葉系幹細胞の調製方法
WO2007031100A1 (en) 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
WO2007061762A2 (en) * 2005-11-18 2007-05-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt And Human Services Non-viral gene delivery complex
WO2007130725A2 (en) * 2006-02-06 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of hmgb1 for protection against ischemia reperfusion injury
JP4982739B2 (ja) 2006-06-01 2012-07-25 国立大学法人 東京医科歯科大学 ポリグルタミン病の予防・治療剤
JP5244785B2 (ja) 2006-08-11 2013-07-24 小野薬品工業株式会社 ストローマ由来因子−１（ｓｄｆ−１）に対するモノクローナル抗体
SI2068935T1 (sl) * 2006-09-15 2011-07-29 Creabilis Therapeutics S R L Polimerni konjugati od Box-A od HMGB1 in Box-A variante od HMGB1
CA2663300C (en) 2006-09-15 2014-10-07 Creabilis Therapeutics S.P.A. Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1
HUE035043T2 (en) 2006-10-30 2018-05-02 Genomix Co Ltd A pharmaceutical composition for promoting functional regeneration of damaged tissue
CA2629652A1 (en) 2007-04-24 2008-10-24 Yaojiong Wu Compositions for preventing or treating skin defects and methods of use thereof
US8114668B2 (en) 2007-05-14 2012-02-14 Cardiac Pacemakers, Inc. Composition for cold storage of stem cells
CN102076350A (zh) 2008-04-30 2011-05-25 吉诺米克斯股份有限公司 将骨髓来源的多能干细胞动员到末梢循环的药物
CN102076351A (zh) 2008-04-30 2011-05-25 吉诺米克斯股份有限公司 损伤组织的功能性再生促进药物
BRPI0911513A2 (pt) 2008-04-30 2016-07-12 Genomix Co Ltd métodos e agentes para coleta de células tronco da medula óssea funcionais in vivo com alta eficiência
EP2488209B1 (en) 2009-10-16 2016-09-28 Rutgers, the State University of New Jersey Method for treating chronic nerve tissue injury using a cell therapy strategy
CN104825491A (zh) 2009-10-28 2015-08-12 吉诺米克斯股份有限公司 利用骨髓间充质干细胞和/或多能干细胞的血中动员的组织再生促进剂
CN102443064A (zh) 2011-11-03 2012-05-09 刘誉 一种基于凝血酶活性的双靶向作用的嵌合多肽及其应用
CA2889275C (en) 2012-10-25 2021-06-15 Katsuto Tamai Novel method for treating cardiac infarction using hmgb1 fragment
RU2649069C2 (ru) 2012-10-25 2018-04-02 Дженомикс Ко., Лтд. Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1

Also Published As

Publication number Publication date
EP2703487A1 (en) 2014-03-05
EP3358011A1 (en) 2018-08-08
CN114106139B (zh) 2024-08-30
CN103687946A (zh) 2014-03-26
JP6069191B2 (ja) 2017-02-01
CA2834255A1 (en) 2012-11-01
JP6336549B2 (ja) 2018-06-06
AU2017203644B2 (en) 2019-05-16
US20140206619A1 (en) 2014-07-24
US10364276B2 (en) 2019-07-30
DK2703487T3 (en) 2018-09-10
US10550165B2 (en) 2020-02-04
US20230212241A1 (en) 2023-07-06
KR101992807B1 (ko) 2019-06-26
JP2021191271A (ja) 2021-12-16
AU2017203644A1 (en) 2017-06-15
US20180072785A1 (en) 2018-03-15
EP2703487A4 (en) 2014-11-12
AU2012248676B2 (en) 2017-04-20
JP6603964B2 (ja) 2019-11-13
JP2017078067A (ja) 2017-04-27
KR20140036202A (ko) 2014-03-25
EP2703487B1 (en) 2018-06-27
AU2022201894B2 (en) 2024-10-10
KR20190073610A (ko) 2019-06-26
PL2703487T3 (pl) 2019-03-29
AU2019210647B2 (en) 2021-12-23
JP2018138049A (ja) 2018-09-06
JPWO2012147470A1 (ja) 2015-02-23
JP2023106525A (ja) 2023-08-01
WO2012147470A1 (ja) 2012-11-01
AU2019210647A1 (en) 2019-08-22
ES2788394T3 (es) 2020-10-21
HK1258536A1 (en) 2019-11-15
PL3358011T3 (pl) 2020-08-24
AU2012248676A1 (en) 2013-11-21
CN103687946B (zh) 2017-05-03
DK3358011T3 (da) 2020-05-11
CN107188948A (zh) 2017-09-22
EP3358011B1 (en) 2020-03-04
PT3358011T (pt) 2020-04-23
US20200369736A1 (en) 2020-11-26
CN114106139A (zh) 2022-03-01
PT2703487T (pt) 2018-10-11
AU2017203644B9 (en) 2019-06-06
ES2684718T3 (es) 2018-10-04
CN107188948B (zh) 2021-11-30
AU2022201894A1 (en) 2022-04-07
KR102113809B1 (ko) 2020-05-21
JP2020058344A (ja) 2020-04-16

Similar Documents

Publication Publication Date Title
AU2022201894B2 (en) Peptide for inducing regeneration of tissue and use thereof
HK1258536B (en) Peptide for inducing regeneration of tissue and use thereof
HK1195101A (en) Peptide for inducing regeneration of tissue and use thereof
HK1195101B (en) Peptide for inducing regeneration of tissue and use thereof
HK1240598B (zh) 用於诱导组织再生的肽及其应用
HK1240598A1 (en) Peptide for inducing regeneration of tissue and use thereof
HK1195584A (en) Peptide for inducing regeneration of tissue and use thereof
HK1195584B (en) Peptide for inducing regeneration of tissue and use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170308